Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,570 result(s) found for: Bone cancer. Displaying page 1 of 179.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-004942-15 Sponsor Protocol Number: CZOL446EIT14 Start Date*: 2005-12-15
    Sponsor Name:NOVARTIS FARMA
    Full Title: A prospective, randomized, multi-center comparative 2-arm trial on efficacy and safety of zoledronic acid every 3-months vs. every 4 weeks beyond approximately 1 year of treatment with zoledronic...
    Medical condition: bone metastasis in patients with breast cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10027452 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-009374-27 Sponsor Protocol Number: 20080540 Start Date*: 2009-08-27
    Sponsor Name:Amgen Inc
    Full Title: An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects with Advanced Cancer or Multiple Myeloma
    Medical condition: Bone metastases in subjects with advanced cancer or multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-018491-24 Sponsor Protocol Number: 31295 Start Date*: 2010-07-15
    Sponsor Name:Vrije Universiteit Medical Center
    Full Title: Effect of aminobisphosphonates and statins on circulating Vy9Vd2-T cells
    Medical condition: patients with malignant bone metastases
    Disease: Version SOC Term Classification Code Term Level
    12.1 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002114-36 Sponsor Protocol Number: 20110113 Start Date*: 2011-10-04
    Sponsor Name:Amgen Inc
    Full Title: Open-Label Access Protocol of Denosumab for Subjects with Advanced Cancer
    Medical condition: Bone Metastases in Subjects with Advanced Breast Cancer and Bone Metastases in Men with Hormone-Refractory Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) AT (Completed) FR (Completed) ES (Completed) PL (Completed) BE (Completed) LV (Completed) LT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000848-65 Sponsor Protocol Number: 20050244 Start Date*: 2006-09-01
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Cancer (Excluding Breast and Prostate...
    Medical condition: Treatment of bone metastases in subjects with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) PT (Completed) AT (Completed) NL (Completed) BE (Completed) HU (Completed) GB (Completed) LT (Completed) DE (Completed) SK (Completed) LV (Completed) SE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-018044-18 Sponsor Protocol Number: TaxiumII Start Date*: 2012-06-22
    Sponsor Name:Meander MC
    Full Title: A randomised phase II study of repeated Rhenium-188 HEDP combined with Docetaxel versus Docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone’
    Medical condition: Men with castration resistant prostate cancer (CRPC) metastatic to bone
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10036921 Prostate carcinoma LLT
    16.1 100000004864 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012189-30 Sponsor Protocol Number: BC1-09 Start Date*: 2009-10-30
    Sponsor Name:Algeta ASA
    Full Title: An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy
    Medical condition: Breast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for further endocrine therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005327-41 Sponsor Protocol Number: INT0211 Start Date*: 2012-04-05
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Clinical trial randomized and controlled to compare the analgesic efficacy of the association zoledronic acid and 153Sm-lexidronam vs zoledronic acid in patients with skeletal metastases from hormo...
    Medical condition: Population enrolled in the study is represented by patients bearing advanced prostatic cancer with skeletal metastases and bone pain cancer-associated and treated with analgesic drugs
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002119-42 Sponsor Protocol Number: 0822-029 Start Date*: 2008-09-23
    Sponsor Name:Merck& Co., Inc.
    Full Title: A Phase III Study to Assess the Tolerability and Efficacy of MK-0822 (Odanacatib) in Reducing the Risk of Bone Metastases and Prolonging Disease-Free Survival in Women with Breast Cancer Spanish t...
    Medical condition: Prevention of disease recurrence in patients with breast cancer. Spanish indication: Prevención de recurrencia de la enfermedad en pacientes con cáncer de mama
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002120-29 Sponsor Protocol Number: 0822-030 Start Date*: 2008-08-13
    Sponsor Name:Merck&Co.,Inc
    Full Title: A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Odanacatib) in Prolonging Bone Metastasis-Free Survival in Men with Castration-Resistant Prostate Cancer
    Medical condition: Prevention of bone metastases in men with prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002669-38 Sponsor Protocol Number: 0822-016 Start Date*: 2006-12-07
    Sponsor Name:Merck & Co Inc.
    Full Title: A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD)
    Medical condition: Metastatic Bone Disease (MBD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) NO (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004879-13 Sponsor Protocol Number: UKF2013/12 Start Date*: 2014-12-08
    Sponsor Name:Universitätsklinikum Freiburg
    Full Title: α-RT; Phase II open-label study to evaluate the efficacy and safety of Radium-223 dichloride in combination with external beam radiotherapy (EBRT) vs. EBRT alone in the treatment of advanced castr...
    Medical condition: Bone metastases in advanced castration resistant prostate carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001621-94 Sponsor Protocol Number: 2007-1805 Start Date*: 2007-08-11
    Sponsor Name:Lothian Health Board [...]
    1. Lothian Health Board
    2. University of Edinburgh
    Full Title: Pregabalin Bone Trial. A double-blind randomised controlled trial of pregabalin versus placebo in conjunction with palliative radiotherapy for malignant bone pain.
    Medical condition: The condition under investigation is cancer induced bone pain (CIBP). This is a major cause of morbidity in patients with cancer and unfortunately standard treatments (including radiotherapy) can b...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027452 Metastases to bone PT
    9.1 10033372 Pain and discomfort NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006195-11 Sponsor Protocol Number: BC1-06 Start Date*: 2008-03-26
    Sponsor Name:Algeta ASA
    Full Title: A double-blind, randomised, multiple dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.
    Medical condition: Hormone refractory prostate cancer with skeletal metastases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027452 Metastases to bone PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) BE (Completed) SK (Completed) ES (Completed) CZ (Completed) NL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001253-41 Sponsor Protocol Number: GOIM16002-CABONESTUDY Start Date*: 2018-03-12
    Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE
    Full Title: Impact of cabazitaxel on metastatic bone disease in patients with castration resistant prostate cancer previously treated with docetaxel
    Medical condition: 1. Histologically or cytologically confirmed adenocarcinoma of prostate that is resistant to hormone therapy and previously treated with a docetaxel containing regimen.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001198 Adenocarcinoma of the prostate metastatic LLT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004513-15 Sponsor Protocol Number: Start Date*: 2005-11-28
    Sponsor Name:Univ. Prof. Dr. Christoph Zielinski
    Full Title: ASSESSMENT OF BIOCHEMICAL MARKERS OF BONE TURNOVER IN PATIENTS WITH METASTATIC BREAST CANCER SWITCHED FROM INTRAVENOUS ZOLEDRONIC ACID THERAPY TO ORAL IBANDRONATE
    Medical condition: Metastatic bone disease due to breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-005088-17 Sponsor Protocol Number: CZOL446EHU03 Start Date*: 2005-05-26
    Sponsor Name:Novartis Hungária Ltd.
    Full Title: A multicenter, Open-label Study to Determine the Effect of I.V. Zometa on Pain and Quality of Life in Patients with Bone Metastases with or without Skeletal Related Events (SREs) Resulting from Bre...
    Medical condition: Patients will have bone metastases with or without skeletal related events (SREs) from breast cancer and prostate cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-000339-93 Sponsor Protocol Number: 20050136 Start Date*: 2006-05-26
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Breast Cancer.
    Medical condition: Treatment of bone metastases in subjects with advanced breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) NL (Completed) SK (Completed) GB (Completed) AT (Completed) ES (Completed) DE (Completed) LT (Completed) EE (Completed) BE (Completed) SE (Completed) LV (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003441-16 Sponsor Protocol Number: ML20570 Start Date*: 2006-12-12
    Sponsor Name:N.V. Roche S.A.
    Full Title: OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS LOADING DOSE OF 3X 6MG IBANDRONIC ACID (BONDRONAT®) DURING 3 CONSECUTIVE DAYS IN PATIENTS WITH BREAST CANCER AND SKELETAL METASTA...
    Medical condition: Metastasic bone pain in patients with breast cancer and bone metastases
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006002 Bone pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000075-16 Sponsor Protocol Number: BAY88-8223/16216 Start Date*: 2012-06-20
    Sponsor Name:Bayer HealthCare AG
    Full Title: Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis
    Medical condition: Castrate Resistant Prostate Cancer/Hormone-Refractory Prostate Cancer patients with bone metastasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10036916 Prostate cancer stage D LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DE (Completed) NO (Completed) FI (Completed) BE (Completed) ES (Completed) CZ (Completed) IE (Completed) GB (Completed) IT (Completed) DK (Prematurely Ended) NL (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 03:01:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA